Literature DB >> 6233298

Disease activity markers in multiple sclerosis. Another look at suppressor cells defined by monoclonal antibodies OKT4, OKT5, and OKT8.

G P Rice, D Finney, S L Braheny, R L Knobler, J C Sipe, M B Oldstone.   

Abstract

Here we report our experience in profiling peripheral blood T-cell subsets with the monoclonal antibodies OKT4, OKT5 , and OKT8. Lymphocyte surface phenotype was measured by automated cytofluorometry. In a population survey, we were unable to detect differences between patients with multiple sclerosis (MS) and control subjects when we compared ratios of lymphocytes of helper cell phenotype (OKT4) to those with suppressor cell phenotype ( OKT5 and OKT8). No differences could be established between patients with stable disease, chronic progressive disease, or those with active disease. In a study of 10 patients followed through an exacerbation, we were also unable to define perturbations in these lymphocyte ratios that correlated with disease activity. Detailed analysis of the fluorescence histogram, which examines the entire spectrum of cell surface fluorescence intensity in a population of lymphocytes, was also not useful in predicting disease activity in these patients. The discrepancies between these data and other reports in the literature are discussed. We propose that these reagents are inadequate indices of disease activity, and that until other monoclonal reagents are developed and studied, the suppressor cell compartment is best assessed by assays of function.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6233298     DOI: 10.1016/0165-5728(84)90028-6

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  20 in total

1.  Dual labelling of circulating CD8 cells in patients with multiple sclerosis.

Authors:  P J Hughes; P F Kirk; D A Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-01       Impact factor: 10.154

2.  Multiple sclerosis: II. Effects of prothymosin alpha on the autologous and allogeneic MLR in patients with multiple sclerosis.

Authors:  G J Reclos; C N Baxevanis; C Sfagos; C Papageorgiou; G C Tsokos; M Papamichail
Journal:  Clin Exp Immunol       Date:  1987-11       Impact factor: 4.330

3.  Determination of activated lymphocytes in peripheral blood of patients with multiple sclerosis.

Authors:  A D Crockard; T A McNeill; J McKirgan; S A Hawkins
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-01       Impact factor: 10.154

4.  Evaluation of evoked potentials and lymphocyte subsets as possible markers of multiple sclerosis: one year follow up of 30 patients.

Authors:  A Ghezzi; M Zaffaroni; D Caputo; R Montanini; C L Cazzullo
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-08       Impact factor: 10.154

5.  Suppressor T cell changes in active multiple sclerosis: analysis with three different monoclonal antibodies.

Authors:  A J Thompson; J Brazil; E A Martin; M Hutchinson; C A Whelan; C Feighery
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-10       Impact factor: 10.154

6.  Factors influencing circulating OKT8 cell phenotypes in patients with multiple sclerosis.

Authors:  P J Hughes; P F Kirk; J Dyas; J A Munro; K I Welsh; D A Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-09       Impact factor: 10.154

7.  Defective autologous mixed lymphocyte reactivity in multiple sclerosis.

Authors:  R L Hirsch
Journal:  Clin Exp Immunol       Date:  1986-04       Impact factor: 4.330

8.  Prolonged dynamic clinico-immunological observation of 85 patients with definite multiple sclerosis: first steps towards monitoring process activity.

Authors:  E I Gusev; T L Demina; A N Boiko; B V Pinegin
Journal:  J Neurol       Date:  1994-07       Impact factor: 4.849

9.  Intrathecal production of neopterin in aseptic meningo-encephalitis and multiple sclerosis.

Authors:  S Fredrikson; P Eneroth; H Link
Journal:  Clin Exp Immunol       Date:  1987-01       Impact factor: 4.330

10.  Antibody to Coxsackie B virus in diagnosing postviral fatigue syndrome.

Authors:  N A Miller; H A Carmichael; B D Calder; P O Behan; E J Bell; R A McCartney; F C Hall
Journal:  BMJ       Date:  1991-01-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.